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Introductory paragraph 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder hallmarked by adult-onset loss of 
motor neurons and fatal paralysis1. Here, we show that mutations in the gene encoding TANK-
binding kinase 1 (TBK1) cause ALS and fronto-temporal dementia (FTD). By exome sequencing of 202 
familial ALS patients and 827 control individuals, we found an exome-wide significant enrichment of 
TBK1 loss-of-function (LoF) mutations in the patient group. Another 4 LoF mutations were identified 
during a subsequent targeted screening of 1076 additional patients. TBK1 mutations co-segregated 
with disease in five families with reduced penetrance. Genetic and biochemical data suggested a 
critical role for the C-terminal TBK1 coiled coil domain (CCD) that mediates binding to the TBK1 
adaptor protein optineurin in neurodegeneration. A mild knock-down of TBK1 expression in zebrafish 
caused shortening and abnormal branching of motor neurons in vivo. We conclude that 
haploinsufficiency of TBK1 causes ALS and dementia/FTD. 
  
Main text 
Mutations in 29 genes have been linked to ALS pathogenesis2,3 and are frequently also associated 
with fronto-temporal dementia (FTD). However, mutations in known ALS genes explain less than 1/3 
of ALS cases 2,3. 
To evaluate low-frequency variants in protein-coding genes DNA samples from 202 familial ALS (fALS) 
patients were selected for exome sequencing. They had been previously screened negative for SOD1 
and C9orf72 mutations and came from families with two or more affected individuals per family from 
the Nordic countries, Germany and Portugal. Control exomes (n=827) from Germany were used to 
compare the variant burden. We used a gene-based test (CMC test,4) to analyze all missense variants 
at four MAF thresholds (MAF <= 5%, 1%, 0.1% and 0.05%). In addition, LoF variants defined as 
nonsense, canonical splice site (within two nucleotides of exon boundary), read-through and 
frameshift variants were investigated separately (MAF <= 5%). While analysis of missense variants 
revealed no prominent hits (Supplementary Fig. 1), the test for LoF variants revealed two outliers, 
TBK1 and IL1RL1, with p-values of 4.048e-7 and 6.982e-9, respectively (Supplementary Fig. 1). IL1RL1 
proved to be a sequencing artifact in a low complexity region, leaving TBK1 as the only candidate. LoF 
variants in TBK1 were absent in controls, whereas ALS patients carried 7 different LoF mutations in 8 
individuals (Table 1, Table 2 and Supplementary Table 1).  
For further evaluation of TBK1 variation, we screened in a second stage additional case and control 
groups using a targeted high resolution melting curve protocol including 50 fALS and 516 sporadic 
ALS (sALS) patients from Sweden, 510 German sALS cases as well as 650 Swedish control subjects. A 
splice site variant was detected in a Swedish fALS patient and another splice site variant was present 
in 3 sALS patients from Sweden and one control individual. 
Clinically, patients carrying TBK1 LoF mutations had a median age of onset of 61 years, 45% showed 
cognitive impairment often progressing to fulminant FTD, and bulbar onset was observed in 36%. 
Table 1 provides an overview of all identified TBK1 variants. It includes TBK1 variants from additional 
1,791 in-house exomes and 63,358 exomes of the ExAC public dataset 5(Table 1 and Supplementary 
Table 1). Accordingly, TBK1 is highly conserved: it does only contain a single variant with a MAF larger 
than 1%. All other 171 non-synonymous variants had a MAF smaller than 0.1%. The presence of 8 LoF 
variants in the ExAC dataset was higher than expected when assuming a lifetime risk for ALS of 
approximately 1 in 450 according to normal population registries 6,7. This is most likely explained by 
the fact that the ExAC dataset is not representative for the general population but contains disease-
specific samples from various exome sequencing projects 5 including schizophrenia, which has been 
clinically linked to ALS 8. 
Co-segregation with ALS or dementia was found in 5 families, confirming causative linkage of TBK1 
LoF mutations with ALS (Fig. 1a–f): TBK1 mutations co-segregated with disease between 2 cousins in 
a Danish Family (Fig. 1a), two second degree relatives in a Swedish family (Fig. 1b), as well as 
between 4 first degree relatives in a German family (Fig. 1c). The identical splice site mutation 
(p.690-713del) was found in a Danish and a Swedish Family but not in over 70 000 controls (Fig. 1e 
and f). This prompted us to undertake genealogical investigations and indeed we could track both 
families to a common ancestor in Sweden 5 generations earlier (Fig. 1e and f). 
Investigation of unaffected individuals provided evidence for reduced penetrance. In family 3 (Fig. 
1b), the p.Ile450LysfsX14 mutation was observed in 3 unaffected individuals who survived the latest 
known onset of disease observed in this family by 11, 14 or 21 years. We also found TBK1 LoF 
mutations in 3 patients who had no reported family history of ALS (Table 2). This is consistent with 
incomplete penetrance and the same pattern has also been found for other ALS mutations in the 
SOD1, C9orf72, FUS, ANG, TDP43, OPTN and p62 genes 2. 
In family 5 (Fig. 1c) a maternally transmitted TBK1(p.Tyr185X) nonsense mutation was observed 
together with a paternal FUS(p.R524G) missense mutation. The TBK1 mutation was associated with 
dementia in the index patient’s mother and the FUS mutation with ALS in her father (Fig. 1c). The 
relative contribution of each variant, both co-segregating with disease in the following generation, 
cannot be determined at this point. However, this observation supports the notion of an oligogenic 
basis of ALS which has previously been reported for other ALS mutations 9. 
Taken together, the highly significant increase in LoF mutational burden in ALS together with co-
segregation with disease demonstrates causality of the identified TBK1 LoF mutations. Consequently, 
we investigated selected mutations in vitro and in vivo in order to clarify the pathogenic mechanisms. 
Most LoF mutations seemed to result in haploinsufficiency. In a patient–derived immortalized 
lymphoblast cell line the splice site mutation c.358+2T>C (p.Thr77TrpfsX3) resulted in a low 
expression of an aberrant splice product the mRNA level, most likely as a consequence of nonsense-
mediated RNA decay, without compensatory upregulation of the wild-type allele at the mRNA or 
protein level (Supplementary Fig. 2). The same mutation expressed in neuronal H4 cells did not 
result in subcellular re-distribution or aggregation of TBK1 (Supplementary Fig. 3). Faint 
immunohistochemical staining intensities of the truncating LoF mutants were in agreement with the 
low expression levels observed by Western blotting (Fig. 2a and f). 
To determine if a subset of the identified missense variants also resulted in a loss-of-function, we 
investigated their kinase activity and ability to bind to substrate and adaptor proteins. Several rare 
missense variants identified in our screens were predicted to impair TBK1 function based on the 
analysis of the TBK1 crystal structure (Supplementary Fig. 4 and 10). p.M559 is predicted to be buried 
in a hydrophobic pocket of the scaffold/dimerization domain (amino acids 408–654) and its 
substitution by an arginine to result in a disturbed protein structure (Supplementary Fig. 4 and 10). 
p.M559R indeed resulted in a complete loss of optineurin (Fig. 2a-c) and interleukin-related factor 3 
(IRF3) binding (Fig. 2e), a loss of TBK1 kinase activity (Fig. 2d and f), and loss of IRF3 activation (Figure 
2f and g). p.M559R is thus likely to result in loss-of-function while the causal relevance of the other 
rare missense variants (Fig. 2) with the exception of p.E696K (see below) cannot be adequately 
judged at this point. A mild knock-down of the TBK1 zebrafish orthologue resulted in shortening and 
abnormal branching of motor neuron axons, further supporting a TBK1 LoF mechanism in vivo (Fig. 
3). Taken together, our data indicate that most pathogenic variants identified represent null 
mutations, and dosage reduction from 2 copies to a single TBK1 copy is sufficient to cause ALS or 
FTD. 
In contrast to the 6 different truncating mutations found in ALS cases (Table 2), the c.2138+2T>C 
splice site mutation co-segregating in the extended Danish/Swedish pedigree over 9 generations (Fig. 
1e) is predicted to result in exon skipping and in-frame deletion of 24 amino acids in the C-terminal 
coiled-coil domain (CCD) of TBK1 (p.690-713del). This domain was shown to mediate the binding to 
various adaptor proteins relevant for TBK1 activation 11. A point mutation in the same CDD (p.E696K) 
was associated with a similar clinical phenotype of progressive bulbar palsy and a disease duration of 
less than 2 years in two different families, supporting causality for this point mutation. Haplotype 
analysis was compatible with a common founder in both families (Supplementary Fig. 5). Therefore, 
the absence or mutation of the C-terminal adaptor-binding CCD of TBK1 seems to be sufficient to 
induce neurodegeneration. Staining of the brain of patient III/3 (Fig. 1e) with the p.690-713del 
mutation revealed Type B TDP-43 positive perinuclear inclusion in neurons in lamina III of the 
temporal lobe and p62 positive perinuclear inclusions in lamina III in the right para-hippocampal 
gyrus (Supplementary Fig. 6). 
Both p.690-713del and p.E696K abolished binding to the prototypic TBK1 adaptor protein optineurin 
(Fig. 2a-c). However, binding to (Fig. 2e) and activation (Figure 2f and g) of IRF3 was unaffected upon 
overexpressin. IRF3 is a TBK1 substrate that binds to the more upstream ubiquitin-like domain (ULD) 
of TBK1 12. The p.E696K mutation we have identified in ALS patients has been employed before as an 
(at that time) “artificial” mutation to dissect the structure/binding properties of the TBK1 C-terminal 
CCD 11. In contrast to the observed loss of optineurin binding (Fig. 2a-c), normal binding of 
TBK1(p.E696K) to other TBK1 adaptor proteins such as TANK, Sintbad and NAP1 was observed 11. 
These findings point to the relevance of the disruption of the CCD for disease causation and suggest 
that loss of TBK1/optineurin interaction is associated with the development of neurodegeneration. 
In summary, we demonstrate that TBK1 haploinsufficiency causes ALS and fronto-temporal 
dementia. As the frequency of TBK1 LoF mutations was 4% in our exome-sequenced cohort of 202 
genetically unexplained fALS index patients, TBK1 mutations may be one of the more common 
genetic causes of ALS among Caucasians. Moreover, our genetic and functional data point to a critical 
role of the C-terminal TBK1 adaptor-binding domain and its interaction with optineurin as a cause of 
neurodegeneration. Earlier studies reported mutations in optineurin 13 and p62/SQSTM1 14, which 
are both autophagy regulating adaptor proteins and substrates of TBK1 15,16, as possible causes of 
ALS. The present results link three ALS-FTD associated genes to a common pathway. 
  
Table 1. TBK1 variants with the respective allele frequencies. 
 
 Variants Cases 
(exomes) 
Cases 
(HRMC
a
) 
Controls 
(HRMC
a
) 
Controls 
(in-house 
exomes) 
Controls 
(ExAC) 
n 189 202 1076 650 2,663 63,358 
LoF 13 8 (2.0%) 4 (0.2%) 1 (0.1%) 0 8 (0.0%) 
Inframe indel 4 0 2 (0.1%) 0 0 48 (0.0%) 
missense 
MAF<=5% 
and >1% 
1 11 (2.7%) 70 (3.3 %) 34 (2.6 %) 105 (2.0%) 1,653 (1.3%) 
missense 
MAF<=1% 
and >0.1% 
0 0 0 0 0 0 
missense 
MAF<=0.1% 
171 4 (1.0%) 13 (0.6%) 4 (0.3%) 28 (0.5%) 781 (0.6%) 
aHigh resolution melting curve analysis. 
 
 
Table 2. List of all loss-of-function mutations and rare missense variants (MAF < 0.0001) detected in 
ALS patients. 
Type of variant Variant 
Predicted 
consequence at 
protein level 
Index patient (if 
respective 
pedigrees is 
displayed in Fig. 1) 
Family 
fALS/
sALS 
Country 
Detection 
method: 
exome 
sequencing 
or HRMCA 
Loss-of-function 
mutations 
958_958delA p.Thr320GlnfsX39 - family 1 fALS Sweden ES 
c.1343_1346delAATT p.Ile450LysfsX14 III/1 (Fig. 1a) family 2 fALS Denmark ES 
c.1343_1346delAATT p.Ile450LysfsX14 III/2 (Fig. 1b) family 3 fALS Sweden ES 
c.1434_1435delTG p.Val479GlufsX3 - family 4 fALS Sweden ES 
c.555T>A p.Tyr185X III/5 (Fig. 1c) family 5 fALS Germany ES 
c.358+2T>C p.Thr77TrpfsX3 III/2 (Fig. 1d) family 6 fALS Germany ES 
c.1340+1G>A p.Ala417X - family 7 fALS Sweden ES 
c.1340+1G>A p.Ala417X - family 8 sALS Sweden HRMCA 
c.1340+1G>A p.Ala417X - family 9 sALS Sweden HRMCA 
c.1340+1G>A p.Ala417X - family 10 sALS Sweden HRMCA 
c.2138+2T>C p.690-713del III/2 (Fig. 1e) family 11 fALS Denmark ES 
c.2138+2T>C p.690-713del IV/2 (Fig. 1f) family 12 fALS Sweden HRMCA 
in-frame deletions 
c.1928_1930delAAG p.Glu643del - family 13 sALS Germany HRMCA 
c.1928_1930delAAG p.Glu643del - family 14 sALS Germany HRMCA 
missense variants 
c.140G>A p.Arg47His - family 15 fALS Germany ES 
c.314A>G Tyr105Ser - family 16 sALS Germany HRMCA 
c.914T>C p.Ile305Thr   family 17 sALS Sweden HRMCA 
c.923G>A p.Arg308Gln - family 18 sALS Sweden HRMCA 
c.1070G>A p.Arg357Gln - family 19 fALS Sweden ES 
c.1676T>G p.Met559Arg - family 20 fALS Portugal ES 
c.1712C>T p.Ala571Val - family 21 sALS Sweden HRMCA 
c.1792A>G p.Met598Val - family 22 sALS Sweden HRMCA 
c.2086G>A p.Glu696Lys - family 23 sALS Sweden HRMCA 
c.2086G>A p.Glu696Lys - family 24 fALS Sweden ES 
Abbreviations: Exome sequencing (ES); High resolution melting curve analysis (HRMCA); familial ALS 
(fALS); sporadic ALS (sALS)  
Main figure Legends 
Figure 1. Pedigrees of ALS families with TBK1 mutations for which co-segregation with disease could 
be assessed. 
Families in (e) and (f) could be linked by a common founder 5 generations earlier. Numbering of 
families refers to the numbering in Table 2. The mutation of each family is given at top of respective 
pedigrees. Haplotype analysis was in agreement with a common founder of families in (e) and (f). 
 
Figure 2. Adaptor protein binding and kinase activity of ALS-associated TBK1 mutations. 
(a) Co-immunoprecipitation (Co-IP) of EGFP-OPTN and Flag-TBK1-WT or the indicated mutants from 
HEK293T cells using anti-Flag agarose. Precipitated proteins were analyzed by immunoblotting (IB) 
with the indicated antibodies. 
(b) Co-IP: Flag-TBK1-WT and the indicated TBK1 mutants (as bait) were purified from HEK293T cell 
lysates with an anti-Flag agarose, followed by incubation with recombinant GST-OPTN. 
(c) GST pull-down assay of Flag-TBK1 (as in b) from HEK293T cells using recombinant, immobilized 
GST-OPTN. Equal GST-OPTN protein levels were confirmed by Ponceau S staining. 
(d) Flag-TBK1-WT and the indicated TBK1 mutants were co-expressed with GFP-OPTN in HEK293T 
cells followed by Western blot analysis. Phosphorylation of S177-OPTN was analyzed with a phospho-
specific antibody (pS177). 
(e) Co-IP of myc-IRF3 and Flag-TBK1-WT or the indicated mutants from HEK293T cells using anti-Flag 
agarose. 
(f-g) Luciferase reporter assay for TBK1-induced promoter activities of IFN-inducible genes. HEK293T 
cells expressing Flag-TBK1-WT or the indicated mutants were harvested for Western blot analysis (f) 
and luciferase assay (g). The internal control was measured by β-GAL activity. Phosphorylation of 
IRF-3 was detected by a phospho-specific antibody (pS396). 
“Δ690-713”, “delA”, “delAATT” and “delTG” (a-c, e-g) refer to the mutations c.2138+2T>C/p.690-
713del, c.958delA/p.Thr320GlnfsX39, c.1343_1346delAATT/p.Ile450LysfsX14 and 
c.1434_1435delTG/p.Val479GlufsX3, respectively. Arrowheads point to Flag-TBK1-WT or truncated 
mutant proteins. 
 
Figure 3. Zebrafish embryos injected with tbk1 morpholinos developed an axonopathy.  
(a) Tbk1 knockdown phenotype was analysed 48 hours after fertilization in zebrafish embryos 
injected with translation (ATG MO) and splicing (SPL MO) blocking morpholinos compared to wild-
type and control injected embryos (CTRL MO).  
(b) Many Tbk1 knockdown zebrafish showed a curved tail phenotype (fixed embryos shown).  
(c) Additionally, motor neuron axons were stained with SV2 and their length and branching were 
assessed.  
(d,e) Tbk1 knockdown induced a shortening and abnormal branching of motor neuron axons. We 
analysed 33 embryos per group and the data represent the average ± sem.  
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Material and Methods 
 
Patients and Ethics statement. All ALS patients were diagnosed according to the EFNS Consensus 
criteria 17. With informed written consent and approved by the national medical ethical review 
boards in accordance with the Declaration of Helsinki (WMA, 1964), EDTA blood samples were drawn 
from control individuals and ALS patients as well as their healthy relatives. Anonymous genotyping of 
healthy risk carriers (relatives of fALS patients) was performed after informed written consent and 
approved by the local medical ethical review boards. Patients were not informed about genetic 
results that were obtained for scientific purposes only, according to the written informed consent. 
DNA was extracted from EDTA blood samples according to standard procedures 18. 
 
Genotyping for SOD1 and C9ORf72 mutations. Mutations in SOD1 and C9ORF72 were excluded 
before exome sequencing of familial ALS cases or high resolution melting curve analysis of Swedish 
ALS patients was performed. SOD1 mutations were exluded by Sanger sequencing of all exons 19. 
Genotyping for extended C9ORF72 hexanucleotide repeat expansions was performed by repeat-
primer PCR with Southern blot confirmation in case of PCR results suggesting a repeat expansion 20. 
 
Whole exome sequencing and sequencing analysis 
Exomes were enriched in solution and indexed with SureSelect XT Human All Exon 50Mb kits, version 
3, 4 and 5 (Agilent Technologies). Sequencing was performed as 75 or 100 bp paired-end reads on 
HiSeq2000/2500 systems (Illumina). For exomes, we generated on average 10.1 (SD ±1.94) gigabases 
of sequence resulting in an average depth of coverage of 123 (SD ±24.0) with 94.4% (SD ±3.4) of the 
target regions covered at least 20 times. Minimal requirements for inclusion were 7 gigabases of 
mapped sequence and 90% of target regions covered at least 20 times. Image analysis and base 
calling was performed using Illumina Real Time Analysis. Reads were aligned against the human 
assembly hg19 (GRCh37) using Burrows-Wheeler Aligner. Multi-sample calling and filtering of all 202 
cases and 2663 controls was performed with GATK (version 3.2-2) HaplotypeCaller and 
VariantRecalibrator as described in the GATK best practices guide 
(https://www.broadinstitute.org/gatk/guide/best-practices). Subsequently, variants overlapping low-
complexity regions were filtered21. Initially, we called on average 25076 variants per exome. The 
VariantRecalibrator removed on average 3371 variants, the low complexity filter 215 variants leaving 
21490 variants per exome. 
The CMC burden test was used as implemented in the EPACTS software, version 3-2-6 
(http://genome.sph.umich.edu/wiki/EPACTS). We compared 202 cases with 827 controls. Controls 
were comprised of healthy parents of children with various diseases, healthy control tissues of 
individuals with tumor diseases and 200 individuals of the KORA study. We performed principal 
component analysis as implemented in the PLINK software package (version 1.07)22. After PCA, we 
removed 7 outliers and subsequently used the first and second principal component as covariates for 
the burden tests. 
 
Screening for TBK1 variants by high resolution melting curve analysis. We used Idaho LightScanner® 
high-resolution melting curve analysis (Biofire Inc.) to screen the coding regions and exon/intron 
boundaries of TBK1 in 1,732 individuals. DNA was analyzed in doublets to prevent false positive 
signals. Samples with aberrant melting patterns were Sanger sequenced to identify the underlying 
variant. Oligonucleotide sequences for 20 amplicons are available on request. 
 
Haplotype analysis. Haplotype blocks were generated using the default algorithm in the program 
Haploview 23. Block definitions are based on Illumina HumanOmni2.5 array data from 500 control 
samples. The haplotype block spanning the TBK1 gene comprises 36 SNP markers (from rs115725023 
to rs7970355) covering a genomic region of 112.7 kb. All variant carriers were genotyped with the 
same Illumina HumanOmni2.5 array and the haplotypes were assigned to the specific haplotypes 
from the TBK1 block definition. 
 
Zebrafish experiments. Morpholinos were purchased from Gene Tools (Philomath): standard control 
morpholino 5’-CCTCTTACCTCAGTTACAATTTATA-3’ (CTRL MO), translation blocking morpholino (ATG 
MO) 5’-CCGTACTCTGCATGATGACTGTA-3’ and splice blocking morpholino (SPL MO) 3’-
GTAGATCCACCTGGACACACACCAC-5’. Morpholinos (4 ng) were injected in 1-2 cell stage zebrafish 
embryos. At 48 hours post fertilization, zebrafish were fixed with 4% PFA and motor neuron axons 
were stained using anti-SV2 antibody (DSHB, Iowa)24. The axonal length was measured in ImageJ and 
the average measure of the 5 last axons above the end of the yolk sac extension was calculated. We 
scored embryos as “embryos with abnormal branching” when two or more axons displayed abnormal 
branching. Protein lysates were prepared in RIPA buffer and analysed by Western blot.  
 
Molecular modeling. The possible effects of the missense variants on TBK1 structure and function 
were assessed based on the TBK1 crystal structure 10. Structural analysis was carried out using COOT 
25, and figures were prepared in PyMOL (www.pymol.org). Based on the analysis, conservative amino 
acid replacements on the protein surface were not studied further. 
 
Neuropathological evaluation and immunohistochemistry. Formalin fixed and paraffin embedded 
sections from the following areas were studied: Left frontal lobe; Right occipital lobe; Left cingulate 
gyrus; Right temporal lobe; Left corpus striatum; Right Thalamus; Right uncus with hippocampus; 
Mesencephalon; Pons; Medulla oblongata; Cervical spinal cord; and Cerebellum. All were 
investigated by routine staining (hematoxylin/eosin, luxol fast blue/cresyl violet, Van Gieson) and by 
immunohistochemistry. The immunohistochemistry were done using the Ventana® BenchMark 
ULTRA system. The following primary antibodies were used: anti-TBK1/NAK (1:25, CCD2 
pretreatment, Cell Signaling Technology® #3013); anti-phosphoTBK1/NAK (1:25, CCD2 pretreatment, 
Cell Signaling Technology® #5483); anti-TDP-43 (1:100, CCD2 pretreatment, Proteintech™ 10782-2-
AP); anti-phosphoTDP-43 (p409/410-1) (1:100, Citrate buffer pH 6.0 microwave pretreatment, Cosmo 
Bio CAC-TIP-PTD-M01); anti-p62 (1:50, CCD2 pretreatment, BD Biosciences 610832); anti-FUS (1:500, 
Citrate buffer pH 6.0 microwave pretreatment, Sigma HPA008784); anti-ubiquitin (1:500, CC1 
pretreatment, Abcam ab7254); anti ubiquilin 2 (5F5) (1:10000, CCD2 pretreatment, Novus Biological 
H00029978-M03). Anti-SOD1 aa 24-39 (purified on Sulfolink coupling gel with SOD1 peptide aa 24-39 
coupled, 1:500, Citrate buffer pH 6.0 microwave pretreatment, Agrisera AS09 535); Anti-SOD1 aa 
131-153 (purified on Sulfolink coupling gel with SOD1 peptide aa 131-153 coupled, 1:1000, Citrate 
buffer pH 6.0 microwave pretreatment, Agrisera AS09 540). 
 
Plasmids and constructs. Supplementary Table 2 summarizes all plasmids used in this study. TBK1 
frameshift mutations and amino acid substitutions were introduced into pEF-BOS Flag-TBK1 wt using 
site directed mutagenesis (Supplementary Table 3). The expression vector for Flag-TBK1 Δ690-713 
mutant was generated by amplifying bp 1-2066 of wt TBK1 from pEF-BOS TBK1 wt using 
oligonucleotides FW and RV(1) (Supplementary Table 4) adding a BamHI restriction site to the 5`-
end. In two subsequent PCRs with oligonucleotides FW and RV(2) or RV(3), respectively, bp 2139-
2190 of wt TBK1 as well as a SalI restriction site were added to the 3`-end of the first PCR product. 
The resulting TBK1 fragment missing bp 2067-2138 was cloned into BamHI and SalI restriction sites of 
pEF-BOS Flag. The correctness of all DNA sequences was verified by sequencing. 
 
Protein expression and purification. GST-fusion proteins were expressed in Escherichia coli BL21 
(DE3) cells in LB medium. Expression was induced by addition of 0.2 mM IPTG and cells were 
incubated at 16°C overnight. Harvested cells were lysed using sonication in a lysis buffer (20 mM 
Tris-HCl pH 7.5, 10 mM EDTA, 5 mM EGTA, 150 mM NaCl) and the supernatant was subsequently 
applied to glutathione sepharose 4B beads (GE Healthcare). After several washes, fusion 
protein-bound beads were used directly in GST pulldown assays or GST-proteins were eluted from 
beads with elution buffer (10 mM glutathione, 50 mM Tris-HCl pH 8.0). 
 
Immunoprecipitation and GST pulldown. HEK293T cells were transfected with expression constructs 
encoding the protein of interest using GeneJuice transfection reagent (Merck Millipore) according to 
the manufacturer’s instructions. 36-48 h post-transfection cells were lysed in lysis buffer (50 mM 
HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 25 mM NaF) supplemented 
with Phosphatase Inhibitor Cocktail 2 (Sigma) and protease inhibitors and supernatants (10 min, 
10.000 x g) were incubated at 4°C for 6 h with GST-fusion protein-bound beads (GST pull down) or for 
1 h with Flag- or GFP-beads (Immunoprecipitation). For immunoprecipitation GFP-Trap beads were 
purchased from ChromoTek and M2 anti-Flag affinity gel from Sigma. After 4 washes with lysis 
buffer, the beads and precipitated proteins were eluted with 2x SDS-PAGE loading buffer, boiled and 
loaded onto 9% SDS-PAGE gels for analysis using chemiluminescence based detection. 
 
Luciferase reporter assay. 0,5x106 HEK293T cells were transfected with (each 0,25ug) pEF-BOS 
Flag-TBK1 constructs and pGL3-IFN-beta as luciferase reporter and pUT651 as β-galactosidase 
reporter using GeneJuice transfection reagent (Merck Millipore). At 48 h post-transfection the cells 
were washed with 1XPBS and lysates were subjected to luciferase assays following the 
manufacturer’s protocol (Roche). Internal control was measured by β-galactosidase activity (Roche). 
Three independent experiments were performed using triplicate samples in each experiment. 
 
Analysis of Lymphoblastoid cell lines (LCLs). Epstein-Barr virus transformed LCLs were generated 
from healthy controls and TBK1 mutant ALS patients carrying the splice site mutation c.358+2C->T or 
the amino acid substitution R47H. Total RNA from LCLs was isolated with the RNeasy Plus Mini Kit 
(Qiagen, Hilden, Germany) and reverse transcription reactions were carried out using the QuantiTect 
Reverse Transcription Kit (Qiagen, Hilden, Germany) according to the manufacturer`s instructions. 
Resulting cDNA was used for subsequent PCR reactions.The region of interest of the TBK1 mRNA was 
amplified by PCR using oligonucleotides 5`-CCTTCGTCCAGTGGATGTTCA-3` and 5`-CACAGACTGTCC-
ATCTTCCCC-3` spanning Exon 3 and 5 (322 bp fragment) and visualized on a 1% Agarose-Gel by 
staining with Ethidium-bromide. Quantitative real-time PCR (qRT-PCR) measurement of TBK1 mRNA 
was performed with a CFX96 Real-Time System (Bio-Rad) using the EXPRESS SYBR GreenER qPCR 
Supermix (life technologies) and oligonucleotides  5`-CGAGATGTGGTGGGTGGAATG-3` and 5`-CACA-
GACTGTCCATCTTCCCC-3`. TBK1 mRNA levels were normalized relative to TBP (TATA Box Binding 
Protein) mRNA using oligonucleotide 5`-CCCATGACTCCCATGACC-3` and 5`-TTTACAACCA-
AGATTCACTGTGG-3` for amplification and 2-ΔΔCt-method for normalization 26. To determine the 
abundance of TBK1 protein, lysates of LCLs were subjected to Western blotting. 
 
Immunocytochemistry of H4 neuronal cells. Neuroblastoma cell line H4 was cultured in DMEM 
(Gibco) + 10% FCS. H4 cells were transfected with pEF-BOS Flag-TBK1 plasmids using SuperFect 
Transfection Reagent (Qiagen, Hilden, Germany) according to the manufacturer`s instructions. 48 h 
post-transfection cells were washed with DPBS (Gibco), fixed for 10 min in 4% paraformaldehyde in 
DPBS, permeabilized for 10 min in DPBS with 100 mM Glycine and 0.1% Triton X-100 (pH 7.4) and 
blocked for 45 min in DBPS with 1.5% BSA and 0.1% Tween 20 (pH 7.4). Primary and secondary 
antibodies were diluted in DPBS and consecutively incubated for 45 min, respectively followed by 
extensive washing in DPBS. Cell nuclei were stained with Hoechst 33258. Pictures were acquired 
using a Zeiss Axio Observer A1 Microscope (HBO 100) and Axio Vision V4.8 sofware. 
 
Antibodies used in this study. Anti‐OPTN (Abcam, ab23666), anti‐myc (Santa Cruz), anti‐GFP (Living 
Colors; Clontech), anti-IRF3 (Cell signaling, #4962), anti‐pIRF3 (Ser396) (Cell signaling, 4D4G), 
anti‐FLAG M2 (Sigma), anti-Vinculin (Sigma, V9131), anti-TBK1 (Pierce, PA5-17478), anti-ß-actin (Cell 
signaling, #4970). The pS177 OPTN antibody was generated by immunoGlobe (as described in 15). 
Secondary HRP conjugated antibodies, goat anti-mouse and goat anti-rabbit IgGs were used for 
immunoblotting. Secondary antibody used for ICC was goat-anti-mouse Dylight 488 (Pierce). 
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